Browse News
Filter News
Found 59 articles
-
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
11/1/2023
The Global Antibiotic Research & Development Partnership (GARDP), in collaboration with Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA), announced today that zoliflodacin, a first-in-class antibiotic, met its primary endpoint in an unprecedented global pivotal Phase 3 clinical trial.
-
Critical agreement paves way for new model to accelerate access to important antibiotics for serious bacterial infections
9/12/2023
A new agreement is poised to accelerate antibiotic access for tens of thousands of patients in regions with the highest rates of antimicrobial resistance.
-
Dried Blood Spot Collection Cards Market Size, Share, Growth Report 2022-2030
9/26/2022
The global dried blood spot collection cards market size was valued at USD 350.6 million in 2021 and it is predicted to hit around USD 517.83 million by 2030 with a CAGR of 4.43% from 2022 to 2030.
-
New Opportunities to Fuel the Expansion of Virtual Clinical Trials Market
8/25/2022
Wilmington, Delaware, United States, Transparency Market Research Inc. - Virtual Clinical Trials (VCTs), also called remote or decentralized trials, are a comparatively new and yet underutilized method of conducting clinical research taking full advantage of technologies such as apps, electronic monitoring devices, and online social engagement platforms
-
Cipla and DNDi launch child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa
6/14/2022
The South African Health Products Regulatory Authority has approved a sweet-tasting, heat-stable, '4-in-1' fixed-dose combination of four antiretroviral treatments composed of abacavir, lamivudine, lopinavir, and ritonavir that is specifically designed for infants and young children with HIV.
-
Pfizer apparently hasn't begun any combination trials in human beings of Paxlovid, and no reported human tests are using the drug in combination with other therapies.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
Leishmaniasis Treatment Market Size, Share, Industry Growth, Trend, Business Opportunities, Challenges, Drivers and Restraint Research Report by 2028
3/23/2022
A disease outbreak takes place when a disease escalates by a higher number than expected in a region or during a season. An outbreak may occur in one community or even extend to several countries altogether.
-
Spurred by Advances in Molecular Diagnostics, Hepatitis Rapid Testing Market Set to Register Positive Growth through 2031
9/21/2021
Fact.MR – A Market Research and Competitive Intelligence Provider: As per the latest Fact.MR analysis, the global hepatitis rapid testing market is forecast to register high growth between 2021 and 2031.
-
The Partnership for Quality Medical Donations to Host Virtual Global Health Policy Forum April 27-29, 2021
4/7/2021
Entitled “The Planet, Pandemics and Possibilities”, the event includes presentations by leading global public health experts Sessions include an in-depth exploration of global health as we enter a new normal, how COVID-19 will change response to future pandemics and strategies for ensuring equity and access to vaccines and quality healthcare
-
Ajinomoto Bio-Pharma Services and DNDi Partner to Develop Critical Immunomodulator for Cutaneous Leishmaniasis Therapeutic
9/29/2020
Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce a strategic supply partnership with the Drugs for Neglected Disease Initiative (DNDi), a collaborative, patients' needs-driven, non-profit drug research and development organization that is developing new treatments for neglected diseases
-
Ascletis Completed Bridging Study of ASC18, a One-pill, Once-a-day Complete HCV Oral Regimen
8/20/2020
Ascletis Pharma Inc. (HKEX code: 1672) announces today that it completed bridging study of ASC18, first one-pill, once-a-day fixed dose combination (FDC) as the complete hepatitis C treatment developed by a Chinese biotech. ASC18 FDC consists of 200 mg Ravidasvir (RDV) and 400 mg Sofosbuvir (SOF). This phase I brid
-
U.S. Food and Drug Administration Approves Lampit® (nifurtimox) for the Treatment of Chagas Disease in Children
8/7/2020
U.S. Food and Drug Administration Approves Lampit ® (nifurtimox) for the Treatment of Chagas Disease in Children Only Chagas disease treatment approved in U.S. for use in children from birth to less than 18 years of age 1 New, dividable tablet specially formulated to disperse in water to assist in administration for pediatric patients 1-3
-
Venatorx Pharmaceuticals and GARDP Partner to Develop New Antibiotic for Hospital Acquired Infections With Limited Treatment Options
4/29/2020
Venatorx Pharmaceuticals and the Global Antibiotic Research and Development Partnership announced a collaboration to accelerate the development of, and access to, cefepime-taniborbactam.
-
Ocugen Appoints Kirsten Castillo and Prabhavathi Fernandes to Board of Directors
4/7/2020
Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage company focused on discovering, developing and commercializing transformative therapies to treat rare and underserved ophthalmic diseases, today announced the appointment of Kirsten Castillo and Prabhavathi Fernandes, Ph.D. to its board of directors.
-
Eisai Provides Tanks to Supply Clean Water to Neglected Tropical Diseases Endemic Regions in Kenya, in Collaboration With Merck
8/27/2019
Eisai Co., Ltd. announced that it provides tanks to supply clean water for the neglected tropical diseases (NTDs) measuresto the endemic regions in Kenya in collaboration with Merck.
-
Takeda Selects Five New Partnerships for Annual Global Corporate Social Responsibility (CSR) Program, Supporting Disease Prevention to Improve Health in Developing and Emerging Countries
6/27/2019
Takeda’s founding mission to serve patients, wherever they are, drives its increased commitments to disease prevention, capacity building, and access to healthcare in developing and emerging countries, in partnership with the global community.
-
DNDi and Atomwise Collaborate to Advance Drug Development Using AI for Neglected Diseases
4/16/2019
Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development
-
Evotec And Gardp Announce New Partnership To Discover Novel Antibiotics
3/19/2019
Collaboration explores opportunities to set up antibiotic discovery and development platform and establish a joint pipeline of novel antibiotic assets
-
Eisai Enters Into Agreement to Support International Ngo Association for Aid and Relief, Japan's Activities in Sudan
2/27/2019
Contributing Further to Patients With Mycetoma, a Neglected Tropical Disease